New scan could reveal hidden cancer spread
NCT ID NCT07457541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a radioactive imaging agent called Technetium-99m HYNIC-FAPI in 15 people with metastatic lung, pancreas, breast, or colorectal cancer. The goal is to see how well it highlights tumors on SPECT/CT scans. Researchers will measure where the agent goes in the body and how it compares to normal tissue, while also checking for safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m HYNIC-FAPI (a radioactive imaging agent)
What this could lead to
If successful, this could provide a new way to see where cancer has spread, helping doctors plan better treatments.
What could go wrong
This is a very early, small study (15 people) focused on imaging, not treatment. It may not lead to any direct benefit for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tomsk National Research Medical Center of the Russian Academy of Sciences
Tomsk, Tomsk Oblast, 634045, Russia